Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure

The proteasome inhibitor Bortezomib is used to treat multiple myeloma (MM). Bortezomib inhibits protein degradation by inactivating proteasomes' active-sites. MM cells are exquisitely sensitive to Bortezomib – exhibiting a low-nanomolar IC50 – suggesting that minimal inhibition of degradation suffic...

Cijeli opis

Bibliografski detalji

Glavni autori:	David S. Pitcher, Kate de Mattos-Shipley, Konstantinos Tzortzis, Holger W. Auner, Anastasios Karadimitris, Maurits F. Kleijnen
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2015-07-01
Serija:	EBioMedicine
Teme:	Multiple myeloma Proteasome Bortezomib CTAB-PAGE Posttranslational modification
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2352396415300219
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!